After months of searching for strategic options, Adaptimmune is offloading its cell therapies to a global pharma, which plans to offer jobs to about half of the biotech’s employees. Once the deal closes, Adaptimmune will reduce its remaining workforce by 62%. Yesterday, the cell therapy biotech entered an agreement with USWM CT, a subsidiary of US WorldMeds Partners, The pharma will pay $55 million in cash for the rights to Adaptimmune’s Tecelra. Source: Fierce Biotech 28/7/2025